CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 18 enrolled
Drug / intervention
Bevacizumab (Avastin)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00555594
NCT00555594Phase 3Completed
CompareCT.gov

Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization

Asociación para Evitar la Ceguera en México·interventional·Posted Nov 8, 2007·Updated Aug 1, 2024

In Brief

A Phase 3 clinical trial evaluating Bevacizumab (Avastin) for Corneal Neovascularization. Completed, enrolled 18 participants across 1 site.

Detailed Summary

To determine the effect of subconjunctival Bevacizumab in corneal neovascularization

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCorneal Neovascularization
CountriesMexico
CollaboratorsNational Council of Science and Technology, Mexico, Universidad Nacional Autonoma de Mexico

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 8, 2007
Enrollment StartSep 1, 2006
Primary CompletionSep 1, 2006
Study CompletionOct 1, 2007
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 18.7 years ago

Interventions

Bevacizumab (Avastin)drug

One dose of 0.1cc of subconjunctival Bevacizumab was applied